A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
Vaccine
; 29(43): 7514-22, 2011 Oct 06.
Article
in En
| MEDLINE
| ID: mdl-21501642
ABSTRACT
We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Plasmodium falciparum
/
Protozoan Proteins
/
Malaria Vaccines
/
Polyproteins
Limits:
Adolescent
/
Adult
/
Humans
/
Middle aged
Language:
En
Journal:
Vaccine
Year:
2011
Document type:
Article
Affiliation country:
United kingdom